Loading...
Market
Story
Merck's HPV Vaccine for Men Approved by China’s Drug Regulator for Ages 9-26, First of Its Kind
Jan 8, 2025, 04:50 AM
China's drug regulator has approved Merck's human papillomavirus (HPV) vaccine for men, marking a significant expansion for the U.S. pharmaceutical company in an emerging market. The vaccine is specifically authorized for males aged 9 to 26 and is the first of its kind in China. This approval comes after a decline in demand among women for the vaccine, which had previously surged. Merck's announcement, made via its Chinese subsidiary, MSD, highlights the potential for growth in a new demographic following the approval by China's medical products administration.
View original story
Similar markets
Zhejiang • 25%
Beijing • 25%
Other • 25%
Shanghai • 25%
Southern China • 25%
Northern China • 25%
Eastern China • 25%
Western China • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Other • 25%
Europe • 25%
North America • 25%
Southeast Asia • 25%
Other • 25%
Beijing • 25%
Shanghai • 25%
Guangdong • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Africa • 25%
Asia • 25%
Europe • 25%
More than 3 million • 25%
2-3 million • 25%
1-2 million • 25%
Less than 1 million • 25%
Northeast • 25%
West • 25%
South • 25%
Midwest • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%
Asia • 25%
Other • 25%
European Union • 25%
United States • 25%
Beijing • 25%
Shanghai • 25%
Guangdong • 25%
Other • 25%